We are live on ! Find out more
CAM

Chou Associates Management Portfolio holdings

AUM $210M
1-Year Est. Return 15.42%
This Fund
S&P 500
This Quarter Est. Return
-0.84%
1 Year Est. Return
+15.42%
3 Year Est. Return
+71.66%
5 Year Est. Return
+124.52%
10 Year Est. Return
+681.17%
AUM
$301M
AUM Growth
-$11.3M
Cap. Flow
-$11.8M
Cap. Flow %
-3.93%
Top 10 Hldgs %
76.26%
Holding
29
New
2
Increased
2
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$11.8M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$7.34M
3
BHC icon
Bausch Health
BHC
+$5.41M
4
SD icon
SandRidge Energy
SD
+$2.15M

Top Sells

Rank Stock Value
1
JPM.WS
JPMorgan Chase
JPM.WS
+$23.3M
2
NOK icon
Nokia
NOK
+$5.03M
3
BAC.WS.A
Bank Of America Corporation Ws A
BAC.WS.A
+$3.44M
4
AZN icon
AstraZeneca
AZN
+$711K
5
GSK icon
GSK
GSK
+$347K

Sector Composition

Rank Sector Weight
1 Financials 29.32%
2 Healthcare 20.58%
3 Consumer Discretionary 10.15%
4 Technology 6.3%
5 Industrials 2.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AZN icon
26
AstraZeneca
AZN
$263B
– –
-6,500
Closed -$711K
GSK icon
27
GSK
GSK
$104B
– –
-14,400
Closed -$347K
1
2

Similar funds

ESC
Eurizon SLJ Capital London $210M AUM
FSA
Financial Services Advisory Rockville, Maryland $210M AUM 19.93% 1-Year Est. Return
WI
Westbourne Investments Arlington, Virginia $210M AUM 40.95% 1-Year Est. Return
UAH
United Airlines Holdings Chicago, Illinois $211M AUM
UI
Unconventional Investor Portsmouth, New Hampshire $211M AUM 14.16% 1-Year Est. Return
PCP
P2 Capital Partners New York $210M AUM 1.23% 1-Year Est. Return
RWRC
R.W. Roge & Company Bohemia, New York $210M AUM 18.75% 1-Year Est. Return
GHP
Great Hill Partners Boston, Massachusetts $210M AUM 134.81% 1-Year Est. Return

Chou Associates Management's Q1 2017 Portfolio in Review

As of Q1 2017, Chou Associates Management held 29 positions worth $301M, down 3.6% from $313M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Chou Associates Management withdrew a net $11.8M in Q1 2017, closing 2 positions and reducing 3 holdings. Its most notable exit was AstraZeneca, an estimated $711K position sold in full.

By sector, the portfolio is most concentrated in Financials at 29% of assets, up from 29% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Chou Associates Management opened a new position in Endo International plc worth $10.6M.

  • Chou Associates Management's largest Q1 2017 buy was Endo International plc: 950,000 shares worth $10.6M.
  • Chou Associates Management added most to Bausch Health in Q1 2017, an estimated $5.41M increase.
  • Chou Associates Management's biggest Q1 2017 reduction was JPMorgan Chase, cutting an estimated $23.3M.
  • Chou Associates Management fully exited AstraZeneca in Q1 2017, selling an estimated $711K.
  • Chou Associates Management's ten largest holdings make up 76% of its $301M portfolio in Q1 2017.
  • Chou Associates Management opened 2 new positions and closed 2 in Q1 2017.
  • Chou Associates Management's portfolio value fell 3.6% quarter-over-quarter to $301M.

Based on Chou Associates Management's 13F filing for Q1 2017, filed 12 May 2017.